uniQure N.V (UQ1) - Net Assets
Based on the latest financial reports, uniQure N.V (UQ1) has net assets worth €149.34 Million EUR (≈ $174.60 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€778.71 Million ≈ $910.39 Million USD) and total liabilities (€629.36 Million ≈ $735.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check uniQure N.V (UQ1) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €149.34 Million |
| % of Total Assets | 19.18% |
| Annual Growth Rate | 13.5% |
| 5-Year Change | -66.61% |
| 10-Year Change | N/A |
| Growth Volatility | 79.54 |
uniQure N.V - Net Assets Trend (2016–2025)
This chart illustrates how uniQure N.V's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see UQ1 stock market capitalisation.
Annual Net Assets for uniQure N.V (2016–2025)
The table below shows the annual net assets of uniQure N.V from 2016 to 2025. Also explore uniQure N.V (UQ1) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €198.90 Million ≈ $232.54 Million |
+3045.81% |
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
-103.25% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
-56.37% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
-20.10% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
+144.27% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
-24.50% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
+79.87% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
+100.99% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
+40.43% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to uniQure N.V's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 93287800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.53 Billion | 768.14% |
| Total Equity | €198.90 Million | 100.00% |
uniQure N.V Competitors by Market Cap
The table below lists competitors of uniQure N.V ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
$1.46 Billion |
|
Energizer Holdings Inc
NYSE:ENR
|
$1.46 Billion |
|
Omnicell Inc
NASDAQ:OMCL
|
$1.46 Billion |
|
Anhui Hengyuan Coal Industry and Electricity Power Co Ltd
SHG:600971
|
$1.46 Billion |
|
Rolls-Royce Holdings PLC
LSE:RR
|
$1.46 Billion |
|
SYoung Group Co Ltd
SHE:300740
|
$1.46 Billion |
|
Liberty Global PLC Class C
NASDAQ:LBTYK
|
$1.46 Billion |
|
Suzhou Oriental Semiconductor Co. Ltd. A
SHG:688261
|
$1.46 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in uniQure N.V's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,752,000 to 198,901,000, a change of 205,653,000.
- Net loss of 198,971,000 reduced equity.
- New share issuances of 391,899,000 increased equity.
- Other factors increased equity by 12,725,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-198.97 Million | -100.04% |
| Share Issuances | €391.90 Million | +197.03% |
| Other Changes | €12.72 Million | +6.4% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares uniQure N.V's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.41x to 12.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €2.85 | €38.25 | x |
| 2018-12-31 | €4.81 | €38.25 | x |
| 2019-12-31 | €7.39 | €38.25 | x |
| 2020-12-31 | €5.45 | €38.25 | x |
| 2021-12-31 | €12.87 | €38.25 | x |
| 2022-12-31 | €10.13 | €38.25 | x |
| 2023-12-31 | €4.34 | €38.25 | x |
| 2024-12-31 | €-0.14 | €38.25 | x |
| 2025-12-31 | €3.18 | €38.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently uniQure N.V utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1236.00%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 4.15x
- Recent ROE (-100.04%) is below the historical average (-56.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -115.31% | -292.35% | 0.13x | 2.99x | €-79.74 Million |
| 2017 | -88.70% | -604.72% | 0.06x | 2.35x | €-88.20 Million |
| 2018 | -46.38% | -738.25% | 0.04x | 1.53x | €-101.26 Million |
| 2019 | -38.45% | -1705.82% | 0.02x | 1.39x | €-156.51 Million |
| 2020 | -51.26% | -333.27% | 0.11x | 1.40x | €-149.41 Million |
| 2021 | 55.32% | 62.90% | 0.65x | 1.36x | €270.01 Million |
| 2022 | -26.64% | -119.07% | 0.15x | 1.48x | €-174.39 Million |
| 2023 | -148.54% | -1947.09% | 0.02x | 4.00x | €-329.25 Million |
| 2024 | 0.00% | -883.35% | 0.05x | 0.00x | €-238.88 Million |
| 2025 | -100.04% | -1236.00% | 0.02x | 4.15x | €-218.86 Million |
Industry Comparison
This section compares uniQure N.V's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $645,377,653
- Average return on equity (ROE) among peers: -63.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| uniQure N.V (UQ1) | €149.34 Million | -115.31% | 4.21x | $1.46 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $1.61 Million | -354.52% | 1.11x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-223.84 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $421.77 Million | -87.98% | 0.40x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.58 Million | -6.53% | 0.28x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more